Brian King
Overview
Brian King is a corporate healthcare associate in the Washington, D.C., office of Kirkland & Ellis LLP. Brian practices within the Firm’s healthcare department and advises his clients on a broad range of regulatory, compliance, transactional and corporate matters, including state and federal fraud and abuse laws, licensure laws, contract negotiations and complex due diligence matters. Brian’s clients include pharmacies, DME/HME providers, laboratories, wholesale distributors, hospitals and surgical centers, PBMs, drug manufacturers, and telehealth/telepharmacy providers, as well as private equity firms, lenders and other healthcare investors.
As both an attorney and a registered pharmacist, he is familiar with the implementation of the Affordable Care Act, HIPAA, Medicare, Medicaid, the False Claims Act and the Federal Anti-Kickback Statute. Brian focuses many aspects of his practice on pharmacy law, where he tackles complex legal issues faced by pharmacies, wholesale distributors, drug and device manufacturers, hospitals, DME suppliers, ambulatory surgical centers and other health care providers. He also has notable experience with controlled substance regulations and is poised to assist clients navigate the opioid crisis. Because of his experience as a pharmacist, he understands many of the unique compliance issues and business objectives that are specific for the healthcare industry.
Experience
Representative Matters
BayPine in its acquisition of CenExel Clinical Research, a provider of a clinical trial site network
Bain Capital-backed QuVa Pharma in its acquisition of LogicStream
Owens & Minor in its proposed $1.4 billion acquisition of Rotech Healthcare Holdings
Waud Capital Partners in its acquisition of Mopec, a provider of anatomic and forensic pathology equipment, technology, consumable products and services, from Blackford Capital
VSP Vision in its acquisition of Eyemart Express from FFL Partners and Leonard Green & Partners
Leerink Partners, Morgan Stanley, Cantor Fitzgerald and Oppenheimer & Co. as placement agents in connection with the $260 million PIPE financing commitment for Helix Acquisition Corp. II (NASDAQ: HLXB), a SPAC sponsored by affiliates of Cormorant Asset Management, to combine with BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics, which was initially formed as a subsidiary of BridgeBio Pharma, Inc. (NASDAQ: BBIO)
Prior Experience
McGuire Woods LLP
Quarles & Brady LLP
More
Credentials
Admissions & Qualifications
- 2025District of Columbia
- 2022North Carolina
- 2017Illinois
Education
- DePaul University College of LawJ.D.2017Health Law Certificate
- Purdue UniversityPharm.D.2008